DRAMATIC, NCT03828201: Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB |
|
|
| Recruiting | 2 | 220 | RoW | Delamanid, Deltyba, Levofloxacin, Levaquin, Bedaquiline, Sirturo, Clofazimine, Lamprene, Linezolid, Zyvox | Boston University, Novartis Pharmaceuticals, Pfizer, Otsuka Pharmaceutical Co., Ltd., University of California, San Francisco, Westat, National Institute of Allergy and Infectious Diseases (NIAID), University of Colorado, Denver, Harvard Medical School (HMS and HSDM), National Lung Hospital, Vietnam, De La Salle Health Sciences Institute, Philippines | Tuberculosis, Multidrug-Resistant | 05/27 | 05/27 | | |
NCT05477186: Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old |
|
|
| Completed | 1 | 180 | US, RoW | CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg), CV0501 (25 μg), CV0501 (50 μg), CV0501 (75 μg), CV0501 (100 μg), CV0501 (150 μg), CV0501 (200 μg) | GlaxoSmithKline | COVID-19, SARS-CoV-2 | 08/23 | 08/23 | | |